Europe Oral Antiviral Market Size, Share & Industry Trends Analysis Report By Indication (Human Immunodeficiency Virus (HIV), Hepatitis, Influenza), By Drug Class, By Distribution Channel, By Country and Growth Forecast, 2023 - 2029

The Europe Oral Antiviral Market would witness market growth of 1.9% CAGR during the forecast period (2023-2029).

People are receiving guidance about viral infections, including hepatitis and influenza, from several groups and the government. Due to consumers' increasing preference for online buying over conventional purchasing methods, e-commerce (or electronic commerce) has emerged as a crucial tool for small and large enterprises worldwide. The market has grown due to various animations used in health apps to inform individuals about HIV infection and medication use. In addition to established nations, developing nations are also showing a desire for potent oral antiviral medications, which is what is driving the market's expansion. In addition, it is anticipated that increased manufacturer promotional efforts and rising public awareness of the need to treat viral infections properly will accelerate the adoption of these technologies in the coming years.

One of the key factors anticipated to drive the growth of the market is the increased prevalence of viral disorders. Growing research funding to create a therapy option that works with ongoing clinical trials is anticipated to drive market expansion. In addition, the top businesses are engaging in mergers and acquisitions to expand the range of treatments available using cutting-edge discoveries like breakthrough immunotherapy medications or other unique formulations.

In Russia, each person spent an average of $140 on prescription drugs in 2018. In the same year, Russia sold over $20.1 billion of pharmaceuticals, accounting for 1.2% of the GDP and 22.1% of the country's total health expenditures. Both prescription and over-the-counter (OTC) medications fall within the pharmaceutical industry in Russia. In general, sales of prescription drugs dominate the pharmaceutical industry, which persisted in 2018 prescription drugs.

The world's largest cooperative healthcare system was established in 1948 with the National Health Services (NHS). It was established to offer healthcare to all individuals and is accessible to all UK residents. The NHA assigns an entity to manage the efficient use of more than £100 billion in funding to commission medical services in England. The expanding pharmaceutical sector and the rising funding will surge investment in the market in the Europe region.

The Germany market dominated the Europe Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $2,673.4 million by 2029. The UK market is showcasing a CAGR of 1.1% during (2023 - 2029). Additionally, The France market would register a CAGR of 2.7% during (2023 - 2029).

Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Worldwide Oral Antiviral Market is Projected to reach USD 41.2 Billion by 2029, at a CAGR of 2.3%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Indication

• Human Immunodeficiency Virus (HIV)
• Hepatitis
• Influenza
• Others

By Drug Class

• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Others

By Distribution Channel

• Drug Store & Retail Pharmacies
• Hospital Pharmacies
• Online Providers

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Gilead Sciences, Inc.
• Viatris, Inc. (Mylan N.V.)
• AbbVie, Inc.
• GlaxoSmithKline PLC (GSK)
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals, Inc.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Oral Antiviral Market, by Indication
1.4.2 Europe Oral Antiviral Market, by Drug Class
1.4.3 Europe Oral Antiviral Market, by Distribution Channel
1.4.4 Europe Oral Antiviral Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Europe Oral Antiviral Market by Indication
3.1 Europe Human Immunodeficiency Virus (HIV) Market by Country
3.2 Europe Hepatitis Market by Country
3.3 Europe Influenza Market by Country
3.4 Europe Others Market by Country

Chapter 4. Europe Oral Antiviral Market by Drug Class
4.1 Europe Reverse Transcriptase Inhibitors Market by Country
4.2 Europe Protease Inhibitors Market by Country
4.3 Europe Others Market by Country

Chapter 5. Europe Oral Antiviral Market by Distribution Channel
5.1 Europe Drug Store & Retail Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country
5.3 Europe Online Providers Market by Country

Chapter 6. Europe Oral Antiviral Market by Country
6.1 Germany Oral Antiviral Market
6.1.1 Germany Oral Antiviral Market by Indication
6.1.2 Germany Oral Antiviral Market by Drug Class
6.1.3 Germany Oral Antiviral Market by Distribution Channel
6.2 UK Oral Antiviral Market
6.2.1 UK Oral Antiviral Market by Indication
6.2.2 UK Oral Antiviral Market by Drug Class
6.2.3 UK Oral Antiviral Market by Distribution Channel
6.3 France Oral Antiviral Market
6.3.1 France Oral Antiviral Market by Indication
6.3.2 France Oral Antiviral Market by Drug Class
6.3.3 France Oral Antiviral Market by Distribution Channel
6.4 Russia Oral Antiviral Market
6.4.1 Russia Oral Antiviral Market by Indication
6.4.2 Russia Oral Antiviral Market by Drug Class
6.4.3 Russia Oral Antiviral Market by Distribution Channel
6.5 Spain Oral Antiviral Market
6.5.1 Spain Oral Antiviral Market by Indication
6.5.2 Spain Oral Antiviral Market by Drug Class
6.5.3 Spain Oral Antiviral Market by Distribution Channel
6.6 Italy Oral Antiviral Market
6.6.1 Italy Oral Antiviral Market by Indication
6.6.2 Italy Oral Antiviral Market by Drug Class
6.6.3 Italy Oral Antiviral Market by Distribution Channel
6.7 Rest of Europe Oral Antiviral Market
6.7.1 Rest of Europe Oral Antiviral Market by Indication
6.7.2 Rest of Europe Oral Antiviral Market by Drug Class
6.7.3 Rest of Europe Oral Antiviral Market by Distribution Channel

Chapter 7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental &Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 SWOT Analysis
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Gilead Sciences, Inc.
7.5.1 Company overview
7.5.2 Financial Analysis
7.5.3 Research & Development Expenses
7.6 Viatris, Inc. (Mylan N.V.)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental Analysis
7.6.4 Research & Development Expense
7.7 AbbVie, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 GlaxoSmithKline PLC (GSK)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Teva Pharmaceutical Industries Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.10. Amneal Pharmaceuticals, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental Analysis
7.10.4 Research & Development Expenses

TABLE 1 Europe Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 2 Europe Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 3 Europe Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 4 Europe Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 5 Europe Human Immunodeficiency Virus (HIV) Market by Country, 2019 - 2022, USD Million
TABLE 6 Europe Human Immunodeficiency Virus (HIV) Market by Country, 2023 - 2029, USD Million
TABLE 7 Europe Hepatitis Market by Country, 2019 - 2022, USD Million
TABLE 8 Europe Hepatitis Market by Country, 2023 - 2029, USD Million
TABLE 9 Europe Influenza Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Influenza Market by Country, 2023 - 2029, USD Million
TABLE 11 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 12 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 13 Europe Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 14 Europe Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 15 Europe Reverse Transcriptase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 16 Europe Reverse Transcriptase Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 17 Europe Protease Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 18 Europe Protease Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 19 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 21 Europe Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 22 Europe Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 23 Europe Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 25 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 27 Europe Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 28 Europe Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 29 Europe Oral Antiviral Market by Country, 2019 - 2022, USD Million
TABLE 30 Europe Oral Antiviral Market by Country, 2023 - 2029, USD Million
TABLE 31 Germany Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 32 Germany Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 33 Germany Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 34 Germany Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 35 Germany Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 36 Germany Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 37 Germany Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 38 Germany Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 39 UK Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 40 UK Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 41 UK Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 42 UK Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 43 UK Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 44 UK Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 45 UK Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 46 UK Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 47 France Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 48 France Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 49 France Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 50 France Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 51 France Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 52 France Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 53 France Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 54 France Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 55 Russia Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 56 Russia Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 57 Russia Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 58 Russia Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 59 Russia Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 60 Russia Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 61 Russia Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 62 Russia Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 63 Spain Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 64 Spain Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 65 Spain Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 66 Spain Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 67 Spain Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 68 Spain Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 69 Spain Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 70 Spain Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 71 Italy Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 72 Italy Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 73 Italy Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 74 Italy Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 75 Italy Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 76 Italy Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 77 Italy Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 78 Italy Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 79 Rest of Europe Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 80 Rest of Europe Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 81 Rest of Europe Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 82 Rest of Europe Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 83 Rest of Europe Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 84 Rest of Europe Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 85 Rest of Europe Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 86 Rest of Europe Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 87 Key information -Johnson & Johnson
TABLE 88 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
TABLE 89 KEY INFORMATION - Merck & Co., Inc.
TABLE 90 Key Information - Bristol Myers Squibb Company
TABLE 91 Key Information - Gilead Sciences, Inc.
TABLE 92 key information - Viatris, Inc.
TABLE 93 Key information - AbbVie, Inc.
TABLE 94 Key Information - GlaxoSmithKline PLC
TABLE 95 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 96 Key Information - Amneal Pharmaceuticals, INc.

List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Oral Antiviral Market Share by Indication, 2022
FIG 3 Europe Oral Antiviral Market Share by Indication, 2029
FIG 4 Europe Oral Antiviral Market by Indication, 2019 - 2029, USD Million
FIG 5 Europe Oral Antiviral Market Share by Drug Class, 2022
FIG 6 Europe Oral Antiviral Market Share by Drug Class, 2029
FIG 7 Europe Oral Antiviral Market by Drug Class, 2019 - 2029, USD Million
FIG 8 Europe Oral Antiviral Market Share by Distribution Channel, 2022
FIG 9 Europe Oral Antiviral Market Share by Distribution Channel, 2029
FIG 10 Europe Oral Antiviral Market by Distribution Channel, 2019 - 2029, USD Million
FIG 11 Europe Oral Antiviral Market Share by Country, 2022
FIG 12 Europe Oral Antiviral Market Share by Country, 2029
FIG 13 Europe Oral Antiviral Market by Country, 2019 - 2029, USD Million
FIG 14 SWOT analysis: Johnson & Johnson